Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Double Blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease

NCT03664674 is registered in ClinicalTrials.gov with Otonomy, Inc. as lead sponsor.

NCT NCT03664674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03664674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Double Blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease
Lead sponsor
Otonomy, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 27, 2018
Completion date
December 22, 2020
Enrollment
148 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

meniere disease